Clinical Trials Logo

Urinary Bladder, Neurogenic clinical trials

View clinical trials related to Urinary Bladder, Neurogenic.

Filter by:

NCT ID: NCT04543552 Completed - Neurogenic Bladder Clinical Trials

A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children

Start date: November 13, 2017
Phase:
Study type: Observational

As a part of the urodynamic studies, urinary catheterization is inserted to measure residual urine, however, it has shown to be an invasive procedure, cause urinary tract infection, and traumatic experience. Bladder scan has been introduced as an alternative and non-invasive method to measure urine residual in the bladder.

NCT ID: NCT04528784 Completed - Multiple Sclerosis Clinical Trials

Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Sclerosis

Start date: October 14, 2020
Phase: N/A
Study type: Interventional

Neurogenic lower urinary tract dysfunction is common among people with Multiple sclerosis with a pooled prevalence of 68.41% using self-report measures and 63.95% using urodynamic studies. Transcutaneous Tibial Nerve Stimulation (TTNS) is a non-invasive treatment option to manage bladder storage symptoms, however, the potential efficacy of TTNS among people with multiple sclerosis is based on a small number of studies with the absence of high-quality evidence relating to efficacy, and lack of clarity of the optimal electrical stimulation parameters and frequency, duration and number of treatment sessions. The feasibility and acceptability of TTNS to manage storage bladder symptoms using Transcutaneous Electrical Nerve Stimulation (TENS) needs to be established before proceeding with a definitive randomised trial. This study aims to assess whether TTNS is feasible and acceptable as a treatment for bladder storage symptoms in people with MS

NCT ID: NCT04483570 Completed - Neurogenic Bladder Clinical Trials

Urological Deterioration in Secondary Tethered Cord Syndrome and Clue to Detect It

Start date: January 2011
Phase:
Study type: Observational

Secondary tethered cord syndrome (STCS) has been diagnosed with signs of progressive deterioration in urological or neuroorthopedic systems following primary tethering surgery. However, there is no convincing urological diagnostic clue for STCS.

NCT ID: NCT04187027 Completed - Neurogenic Bladder Clinical Trials

Efficacy Of Pulsed Electromagnetic Field Therapy On Neurogenic Bladder in Children With Myelomeningocele

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

This study was conducted to assess the efficacy of pulsed electromagnetic field therapy on neurogenic bladder in children with myelomeningocele .Intervention: A pretest-post test controlled study was conducted in out-patient clinic in faculty of physical therapy Cairo university.

NCT ID: NCT04170413 Completed - Neurogenic Bladder Clinical Trials

Feasibility of Using Contrast Enhanced Voiding Urosonography (CeVUS) During Urodynamic Studies

Start date: January 1, 2020
Phase:
Study type: Observational

The investigators will assess the feasibility of replacing fluoroscopy/iodinated contrast with ultrasound/sulfur hexafluoride lipid-type A microspheres during routine urodynamic studies.

NCT ID: NCT04074616 Completed - Neurogenic Bladder Clinical Trials

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

TTNS-RCT
Start date: November 19, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (TTNS) in spinal cord injury(SCI) and to determine the impact on quality of life using TTNS at home

NCT ID: NCT04072796 Completed - Neurogenic Bladder Clinical Trials

Neurogenic Bladder and Quality of Life in Patients With Stroke

Start date: January 15, 2015
Phase:
Study type: Observational [Patient Registry]

This study investigated effects of the neurogenic bladder on the quality of life in stroke survivors. Patients were divided into two groups: the First group consisted of patients with neurogenic bladder and the Second group consisted of patients without neurogenic bladder.

NCT ID: NCT04063852 Completed - Multiple Sclerosis Clinical Trials

PTNS on Urinary and Global Quality of Life in MS Patients

PTNSinMS
Start date: February 27, 2019
Phase:
Study type: Observational

This is a single-centered, prospective, longitudinal, observational cohort study of patients with MS who suffer from lower urinary tract symptoms (LUTS) and are refractory to two prior treatment modalities who have elected to pursue PTNS therapy for LUTS.

NCT ID: NCT03964077 Completed - Clinical trials for Spinal Cord Injuries

Turkish Version of the Neurogenic Bladder Symptom Score Questionnaire: a Cross-cultural Adaptation, Reliability and Validity Study

Start date: June 1, 2019
Phase:
Study type: Observational

Turkish version of the Neurogenic Bladder Symptom Score questionnaire: a cross-cultural adaptation, reliability and validity study

NCT ID: NCT03908047 Completed - Clinical trials for Spinal Cord Injuries

Functional Changes in the Brain After Tibial Nerve Stimulation: a Pilot Study

Start date: July 15, 2019
Phase:
Study type: Observational

The lower urinary tract is innervated by the autonomous (sympathetic, parasympathetic) and the somatic nervous system. Afferent information from the lower urinary tract (LUT) (e.g. filling state and volume of the urinary bladder) is conducted via the dorsal roots to the sacral spinal cord and from there to the pontine micturition center (PMC) in the brain stem. The PMC has several connections to other cortical areas. These complex interactions with the cortex enable voluntary control of the LUT and are crucial for urinary continence. The integrity of this neuronal circuit is crucial for an undisturbed function. Deterioration of the nerve fibers due to a systemic neurological disease (e.g. spinal cord injury) can affect LUT function. Neurogenic lower urinary tract dysfunction can lead to urgency, urge incontinence, reduced bladder capacity and secondary deterioration of the upper urinary tract (i.e. kidneys). First-line therapy of neurogenic detrusor overactivity contains antimuscarinic treatment. In case of side effects or remaining detrusor overactivity, nerve stimulation (e.g. sacral neuromodulation and in effect nerve tibialis stimulation) is an accepted therapy option. The precise mechanism of action of these neuro-modulatory procedures is still unknown. Utilizing state-of-the-art neuroimaging techniques, we intend to investigate the functional activation pattern after afferent tibialis nerve stimulation as well as the association with the architecture of the sacral roots. We aime to get a better insight into functional neuromodulation and central nervous processing. The study aim is to evaluate the feasibility in healthy subjects as a pilot study for the application of these method in patients with chronic, incomplete spinal cord injury.